Please login to the form below
Spark Therapeutics
This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Roche to collaborate with Dyno on gene therapies for CNS/liver diseases
As part of the collaboration, Dyno will be responsible for the design of the novel AAV capsids, while Roche and its Spark Therapeutics division will develop the capsids in preclinical studies, ... This new partnership represents Dyno’s largest
Latest news
-
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
Also in the running is SPK-8011 from Spark Therapeutics – although this contender suffered a setback in 2018 after two patients treated with the therapy developed immune reactions.
-
Roche pays $1.15bn for Sarepta’s Duchenne gene therapy
Pens another gene therapy deal following takeover of Spark Therapeutics. Fresh from its drawn-out takeover of Spark Therapeutics, Roche has signed another gene therapy deal, licensing Sarepta’s Duchenne muscular
-
Roche to close $4.3bn Spark deal after FTC clearance
Comes on the heels of CMA green light. After ten long months of waiting, Roche can finally go-ahead with its $4.3bn takeover of gene therapy specialist Spark Therapeutics, following ... with and into Spark without a vote or meeting of Spark’s
-
UK’s CMA clears Roche’s $4.3bn takeover of Spark
Roche first announced deal in February. Its a happy day for Roche, as it clears one of the hurdles in the way of its $4.3 acquisition of Spark Therapeutics, after ... Adding Spark’s gene therapies SPK-8011 and earlier-stage follow-up SPK-8061 for
-
Sangamo steps up BioMarin chase with haemophilia gene therapy data
data to come in on all the near-term candidates – which also includes Spark Therapeutics’ SPK-8011 – to see which has the best clinical profile. ... Spark suffered a setback last year after two patients treated with SPK-8011 developed immune
More from news
Approximately 17 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Recent examples of this trend can be seen in Roche’s December 2019 $4.8bn takeover of Spark Therapeutics, one of the first US gene therapy firms to succeed in obtaining
-
Alzheimer’s: the search for a cure
Pharma’s return? Positive data on one of the combinations or approval of aducanumab could spark renewed interest in treating Alzheimer’s. ... Such a shift has recently happened in the gene therapy space, which was a backwater pursued largely by
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close to that $1m mark. ... Fellow US gene therapy company Spark was acquired by Roche for $4.3bn in
-
Drug launches to watch in 2019
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Unlike fellow Boston, MA-based gene therapy company Spark
-
The European Medicines Agency: PRIME’d for access?
sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Industry appointments
Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Account Director
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Lead Copywriter
-
Competitive
- Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%
- BMS gains FDA approval for second Opdivo combo in kidney cancer
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant
- New study identifies drugs that are safe to use in COVID-19 treatment
- Regeneron’s antibody cocktail prevents COVID-19 in high-risk patients
- Moderna’s COVID-19 vaccine appears effective against UK and South Africa variants
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- UK study finds antibiotics azithromycin and doxycycline ineffective against COVID-19
- Merck ends its COVID-19 vaccine programme after disappointing early trial results
- Wilmington Healthcare appoints new Head of Digital
PMHub
Apex.co.uk Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...
Latest intelligence
- An EU emergency health fund to limit the impact of future crises
- Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
Quick links
Infographics
